Psoriasis is a skin disease caused by a weak immune system that affects people aged 11 to 45 years old. It is characterized by a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk and scalp.

Recent research has identified the cause of psoriasis to be in the gut and not the skin. Accumulation of harmful toxins in the body for long periods of time induce the detoxifying reaction of the body to occur through the skin, thus, causing psoriasis plaques. Hence, psoriasis is the external manifestation of the body’s attempt to rid itself of internal toxins.

Although there is still no definitive cure for psoriasis, there are a number of treatments that help people manage the symptoms.

There are natural methods that can reduce the burning sensation and inflammation, therefore, significantly improving the appearance of the skin.

Acupuncture helps restore balance to the body. Thus, by bringing the body back to harmony the disease can be cured.

Change in diet and lifestyle may help reduce the symptoms of Psoriasis. 

  • Coating with a mixture of essential oils
  • Washing the body only with handmade olive oil soap (green soap)
  • Avoiding stressful situations, alcohol, smoking.


  • Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017 Apr;63(4):278-285.
  • Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019 Sep 5;20(18):4347.
  • Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017 Nov 1;18(11):2297.
  • Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023 Mar 4;401(10378):747-761.